Best Stocks Under $50 Right Now It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $50.00 (50 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts. #1 - Doman Building Materials GroupOTCMKTS:CWXZFStock Price: $5.75 (+$0.08)P/E Ratio: 13.51Average Trading Volume: 2,438 sharesDividend Yield: 10.46%<Consensus Rating: Strong Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $10.00 (73.9% Upside)Doman Building Materials Group Ltd., through its subsidiaries, engages in the wholesale distribution of building materials and home renovation products for new home construction, home renovation, and industrial markets primarily in the United States and Canada. It distributes a range of building materials, lumber, and renovation products. The company also produces and treats lumber; and provides other value-add services. In addition, it is involved in agricultural post-peeling and pressure treating activities. The company was formerly known as CanWel Building Materials Group Ltd. and changed its name to Doman Building Materials Group Ltd. in May 2021. Doman Building Materials Group Ltd. was founded in 1989 and is headquartered in Vancouver, Canada. Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. #2 - EveriNYSE:EVRIStock Price: $10.65 (+$0.26)P/E Ratio: 9.18Market Cap: $910.89 millionAverage Trading Volume: 865,464 sharesConsensus Rating: Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $20.00 (87.9% Upside)Everi Holdings Inc. develops and supplies entertaining game content, gaming machines, and gaming systems and services for land-based and iGaming operators in the United States, Canada, Australia, the United Kingdom, Europe, the Caribbean, Central America, and Asia. It operates in two segments, Games and Financial Technology Solutions. The company offers classic mechanical reel games and video reel games, as well as TournEvent of Champions, a national slot tournament; and sells gaming equipment and player terminals, licenses, game content, and ancillary equipment, such as signage and lighting packages. It also provides financial access services, such as funds dispensed and transmitted, credit card and POS debit card financial access transactions; check warranty; CashClub, a software payments platform that provides gaming operators with a personal computer workstation software user interface and point-of-sale terminal; CashClub Wallet, a digital payments platform for gaming operators; fully integrated kiosks that provide multiple functions to gaming operators on their casino floors; loyalty kiosk and related equipment; and other integrated kiosk solutions. In addition, the company offers non-funds dispensing terminals that perform authorizations for credit card financial access and POS debit card financial access transactions; and database services. Further, it provides Everi Compliance, a anti-money laundering management tool; Central Credit, a gaming patron credit bureau service; JackpotXpress, a jackpot payout and tax form management platform; and Loyalty platform, a software platform to adopt and deliver new promotional strategies, as well as support and maintenance services. It offers products for the casino, sports, entertainment, and hospitality industries. The company was formerly known as Global Cash Access Holdings, Inc. and changed its name to Everi Holdings Inc. in August 2015. Everi Holdings Inc. was founded in 1998 and is based in Las Vegas, Nevada.#3 - NkartaNASDAQ:NKTXStock Price: $10.96 (+$0.80)P/E Ratio: -4.38Market Cap: $537.81 millionAverage Trading Volume: 3.55 million sharesConsensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $14.80 (35.0% Upside)Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.#4 - Iridium CommunicationsNASDAQ:IRDMStock Price: $34.43 (+$0.78)P/E Ratio: -191.27Market Cap: $4.26 billionAverage Trading Volume: 729,226 sharesDividend Yield: 1.51%<Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $61.75 (79.3% Upside)Iridium Communications Inc. provides mobile voice and data communications services and products to businesses, the United States and international governments, non-governmental organizations, and consumers worldwide. The company offers postpaid mobile voice and data satellite communications; prepaid mobile voice satellite communications; push-to-talk; broadband data; and Internet of Things (IoT) services. It also provides hosted payload and other data services, such as satellite time and location services; and inbound connections from the public switched telephone network, short message, subscriber identity module, activation, customer reactivation, and other peripheral services. In addition, the company offers voice and data solutions comprising personnel tracking devices; asset tracking devices for equipment, vehicles, and aircrafts; beyond-line-of-sight aircraft communications applications; maritime communications applications; specialized communications solutions for high-value individuals; mobile communications and data devices for the military and intelligence agencies, such as secure satellite handsets, as well as netted voice, messaging, and paging services; and maintenance services for the United States government's dedicated gateway. Further, it provides satellite handsets, voice and data modems, broadband data devices, and IoT data devices; various accessories for its devices that include batteries, holsters, earbud headphones, portable auxiliary antennas, antenna adaptors, USB data cables, charging units, and others; and engineering and support services. Iridium Communications Inc. sells its products and services to commercial end users through a wholesale distribution network that include service providers, and value-added resellers and manufacturers. The company was formerly known as Iridium Holdings LLC and changed its name to Iridium Communications Inc. in September 2009. Iridium Communications Inc. is headquartered in McLean, Virginia.#5 - Zura BioNASDAQ:ZURAStock Price: $3.92 (-$0.08)Market Cap: $168.91 millionAverage Trading Volume: 209,658 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $16.60 (323.5% Upside)Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.#6 - HarmonicNASDAQ:HLITStock Price: $13.00 (+$0.06)P/E Ratio: 18.31Market Cap: $1.46 billionAverage Trading Volume: 2.53 million sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $17.20 (32.3% Upside)Harmonic Inc., together with its subsidiaries, provide video delivery software, products, system solutions, and services worldwide. The company operates in two segments, Video and Broadband. The Video segment sells video processing, production, and playout solutions and services to broadband operators, and satellite and telecommunications Pay-TV service providers, as well as to broadcast and media, including streaming media companies. This segment's video processing appliance solutions include network management and application software, and hardware products, such as encoders, video servers, high-density stream processing systems, and edge processors. This segment also provides software-as-a-service (SaaS) solutions, which enables the packaging and delivery of streaming services, including live streaming, video-on-demand, catch-up TV, start-over TV, network-DVR, and cloud-DVR services through HTTP streaming to various device along with dynamic and personal ad insertion. The Broadband segment offers CableOS software-based broadband access solutions; and CableOS central cloud services primarily to broadband operators. Its products enable customers to create, prepare, store, playout, and deliver a range of broadcast and streaming video services to consumer devices, including televisions, personal computers, laptops, tablets, and smart phones. The company also provides technical support and professional services, such as maintenance and support, consulting, implementation, program management, technical design and planning, building and site preparation, integration and equipment installation, end-to-end system testing, and training, as well as SaaS-related support and deployment. It sells its products through its direct sales force, as well as through independent resellers and systems integrators. Harmonic Inc. was incorporated in 1988 and is headquartered in San Jose, California.#7 - Kimbell Royalty PartnersNYSE:KRPStock Price: $15.27 (+$0.19)P/E Ratio: 12.12Market Cap: $1.45 billionAverage Trading Volume: 406,879 sharesDividend Yield: 13.71%<Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $20.33 (33.2% Upside)Kimbell Royalty Partners, LP, together with its subsidiaries, engages in acquiring and owning mineral and royalty interests in oil and natural gas properties in the United States. The company serves as the general partner of the company. Kimbell Royalty Partners, LP was incorporated in 2015 and is based in Fort Worth, Texas.#8 - ArdelyxNASDAQ:ARDXStock Price: $9.27 (+$0.30)P/E Ratio: -77.25Market Cap: $2.15 billionAverage Trading Volume: 6.84 million sharesConsensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $11.92 (28.6% Upside)Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.#9 - QuanterixNASDAQ:QTRXStock Price: $24.35 (+$0.58)P/E Ratio: -23.64Market Cap: $921.16 millionAverage Trading Volume: 280,188 sharesConsensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $31.60 (29.8% Upside)Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables, such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, custom development, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.#10 - Mirum PharmaceuticalsNASDAQ:MIRMStock Price: $27.02 (+$0.26)P/E Ratio: -6.28Market Cap: $1.26 billionAverage Trading Volume: 665,579 sharesConsensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $54.13 (100.3% Upside)Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.#11 - DigitalBridge GroupNYSE:DBRGStock Price: $19.90 (+$0.70)P/E Ratio: -94.73Market Cap: $3.25 billionAverage Trading Volume: 1.87 million sharesDividend Yield: 0.21%<Consensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $21.94 (10.3% Upside)DigitalBridge is an infrastructure investment firm specializing in digital infrastructure assets. They provide services to institutional investors. They primarily invest in data centers, cell towers, fiber networks, small cells, and edge infrastructure. DigitalBridge Group, Inc. was founded in 1991 and is headquartered in Boca Raton, Florida with additional offices in Los Angles, California, and New York New York.#12 - Fusion PharmaceuticalsNASDAQ:FUSNStock Price: $11.32 (-$0.51)P/E Ratio: -6.94Market Cap: $819.68 millionAverage Trading Volume: 1.32 million sharesConsensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $13.80 (21.9% Upside)Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. Its lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers. The company has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.#13 - Delta Air LinesNYSE:DALStock Price: $40.35 (+$0.13)P/E Ratio: 5.64Market Cap: $25.96 billionAverage Trading Volume: 12.30 million sharesDividend Yield: 1.00%<Consensus Rating: Buy (9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $55.54 (37.7% Upside)Delta Air Lines, Inc. provides scheduled air transportation for passengers and cargo in the United States and internationally. The company operates through two segments, Airline and Refinery. Its domestic network centered on core hubs in Atlanta, Minneapolis-St. Paul, Detroit, and Salt Lake City, as well as coastal hub positions in Boston, Los Angeles, New York-LaGuardia, New York-JFK, and Seattle; and international network centered on hubs and market presence in Amsterdam, Mexico City, London-Heathrow, Paris-Charles de Gaulle, and Seoul-Incheon. The company sells its tickets through various distribution channels, including delta.com and the Fly Delta app, reservations, online travel agencies, traditional brick and mortar, and other agencies. It also provides aircraft maintenance and engineering support, repair, and overhaul services; and vacation packages to third-party consumers, as well as aircraft charters, and management and programs. The company operates through a fleet of approximately 1,250 aircrafts. Delta Air Lines, Inc. was founded in 1924 and is based in Atlanta, Georgia.#14 - Atlas Energy SolutionsNYSE:AESIStock Price: $17.28 (+$0.18)Market Cap: $1.73 billionAverage Trading Volume: 568,028 sharesDividend Yield: 3.46%<Consensus Rating: Buy (10 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $24.90 (44.1% Upside)Atlas Energy Solutions Inc. provides proppant and logistics services to the oil and natural gas industry within the Permian Basin of West Texas and New Mexico. The company was founded in 2017 and is based in Austin, Texas.#15 - CymaBay TherapeuticsNASDAQ:CBAYStock Price: $24.96 (+$0.96)P/E Ratio: -27.13Market Cap: $2.83 billionAverage Trading Volume: 1.23 million sharesConsensus Rating: Buy (12 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $23.70 (-5.0% Upside)CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.#16 - Innergex Renewable EnergyOTCMKTS:INGXFStock Price: $6.04 (-$0.19)P/E Ratio: -46.46Market Cap: $1.23 billionAverage Trading Volume: 6,655 sharesDividend Yield: 8.52%<Consensus Rating: Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $25.60 (323.8% Upside)Innergex Renewable Energy Inc. operates as an independent renewable power producer in Canada, the United States, France, and Chile. It acquires, owns, develops, and operates hydroelectric facilities, and wind and solar farms, as well as energy storage facilities. The company operates through three segments: Hydroelectric Power Generation, Wind Power Generation, and Solar Power Generation. It owns and operates 84 facilities with a net installed capacity of 4,184 megawatts, which include 40 hydroelectric facilities, 35 wind facilities, and 8 solar farms. Innergex Renewable Energy Inc. is headquartered in Longueuil, Canada.#17 - Spruce BiosciencesNASDAQ:SPRBStock Price: $3.98 (-$0.11)P/E Ratio: -2.67Market Cap: $162.03 millionAverage Trading Volume: 249,816 sharesConsensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $7.67 (92.6% Upside)Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.#18 - Integra ResourcesNYSEAMERICAN:ITRGStock Price: $0.81 (-$0.04)P/E Ratio: -1.26Market Cap: $55.51 millionAverage Trading Volume: 53,809 sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $4.00 (396.5% Upside)Integra Resources Corp., a precious metals exploration and development company, engages in the acquisition, exploration, and development of mineral properties in the Great Basin of the Western United States. The company explores for gold and silver deposits. It primarily focuses on developing DeLamar Project located in southwestern Idaho; and the Wildcat and Mountain View Projects located in western Nevada. It also holds a portfolio of early-stage exploration projects in Idaho, Nevada, and Arizona. The company was formerly known as Mag Copper Limited and changed its name to Integra Resources Corp. in August 2017. Integra Resources Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.#19 - MP MaterialsNYSE:MPStock Price: $16.43 (-$0.12)P/E Ratio: 28.33Market Cap: $2.92 billionAverage Trading Volume: 2.51 million sharesConsensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $31.57 (92.2% Upside)MP Materials Corp., together with its subsidiaries, produces rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth mine and processing facility in North America. It holds the mineral rights to the Mountain Pass mine and surrounding areas, as well as intellectual property rights related to the processing and development of rare earth minerals. The company was founded in 2017 and is headquartered in Las Vegas, Nevada.#20 - KingfisherOTCMKTS:KGFHYStock Price: $5.59 (+$0.08)Market Cap: $5.24 billionAverage Trading Volume: 159,206 sharesDividend Yield: 2.99%<Consensus Rating: Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/AKingfisher plc, together with its subsidiaries, supplies home improvement products and services primarily in the United Kingdom, Ireland, France, and internationally. The company also offers property investment, finance, digital, sourcing, and IT services. It also operates retail stores under the B&Q, Castorama, Brico Dépôt, Screwfix, TradePoint, and Koçtas brands. The company sells its products through stores and e-commerce channels. Kingfisher plc was incorporated in 1982 and is headquartered in London, the United Kingdom.#21 - ATINYSE:ATIStock Price: $40.74 (+$0.60)P/E Ratio: 16.23Market Cap: $5.20 billionAverage Trading Volume: 1.40 million sharesConsensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $51.40 (26.2% Upside)ATI Inc. manufactures and sells specialty materials and components worldwide. It operates in two segments: High Performance Materials & Components (HPMC) and Advanced Alloys & Solutions (AA&S). The HPMC segment produces various materials, including titanium and titanium-based alloys, nickel- and cobalt-based alloys and superalloys, advanced powder alloys and other specialty materials, in long product forms, such as ingot, billet, bar, rod, wire, shapes and rectangles, and seamless tubes, as well as precision forgings, components, and machined parts. The segment serves aerospace and defense, medical, and energy markets. The AA&S segment produces zirconium and related alloys, including hafnium and niobium, nickel-based alloys, titanium and titanium-based alloys, and specialty alloys in a variety of forms, such as plate, sheet, and precision rolled strip products. It also provides hot-rolling conversion services, including carbon steel products. This segment offers its solutions to the energy, aerospace and defense, automotive, and electronics markets. The company was formerly known as Allegheny Technologies Incorporated. ATI Inc. was founded in 1960 and is headquartered in Dallas, Texas.#22 - ImmunovantNASDAQ:IMVTStock Price: $35.27 (+$0.03)P/E Ratio: -17.90Market Cap: $5.10 billionAverage Trading Volume: 1.33 million sharesConsensus Rating: Buy (13 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $46.92 (33.0% Upside)Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.#23 - RAPT TherapeuticsNASDAQ:RAPTStock Price: $25.36 (-$0.43)P/E Ratio: -8.81Market Cap: $872.38 millionAverage Trading Volume: 423,286 sharesConsensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $36.33 (43.3% Upside)RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.#24 - K92 MiningOTCMKTS:KNTNFStock Price: $4.91 (-$0.07)Average Trading Volume: 78,509 sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $9.38 (91.1% Upside)K92 Mining Inc. engages in the mining, exploration, and development of mineral deposits in Papua New Guinea. The company produces gold, copper, and silver. The company's mineral properties include the Kainantu gold mine project that covers an area of 836.8 square kilometers located in the Eastern Highlands province of Papua New Guinea; and the Blue Lake gold-copper porphyry deposit located in the southwest of the Kora and Judd intrusion. K92 Mining Inc. is headquartered in Vancouver, Canada.#25 - Intuitive MachinesNASDAQ:LUNRStock Price: $3.78 (+$0.28)Market Cap: $347.53 millionAverage Trading Volume: 1.77 million sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $10.00 (164.6% Upside)Intuitive Machines, Inc. designs, manufactures, and operates space products and services in the United States. Its space systems and space infrastructure enable scientific and human exploration and utilization of lunar resources to support sustainable human presence on the moon. The company offers µNova, a lunar rocket-fueled drone, lunar surface rover services, fixed lunar surface services, rideshare delivery services, lunar access services, lunar orbit delivery services, and lunar data network services, as well as content sales and marketing. It also offers aerospace engineering services to NASA and the aerospace industry. Intuitive Machines, Inc. was founded in 2013 and is based in Houston, Texas. More Stock Ideas from MarketBeat Stock Lists: 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks: Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange: NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEMKT Stocks NYSEARCA Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas: Disney stock rising: The house of mouse is back! Archer Aviation's sky-high progress and short interest Cirrus Logic: A chip stock you're going to hear a lot more about Can Etsy stock craft rebound with support from big investor? 3 education stocks breaking out on a hiring spree e.l.f. Beauty on a shelf; a good time to buy Can financial, healthcare, energy stocks rise as rates stay high? Roblox is turning a corner, but can it complete a reversal? Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.